Curb Your BioTech cover art

Curb Your BioTech

Curb Your BioTech

By: Medistrava
Listen for free

LIMITED TIME OFFER | £0.99/mo for the first 3 months

Premium Plus auto-renews at £8.99/mo after 3 months. Terms apply.

About this listen

 The inside discussion on biotechnology business. Built by biotechnology executives for biotechnology executives or anyone interested in learning more about the business of biotech. This covers a mix of topics including sector business outlook, biotech news, advice on founding and scaling a biotech business, and current trends that impact executivesCopyright 2022 All rights reserved. Economics Management Management & Leadership
Episodes
  • JP Morgan Conference Discussion

    JP Morgan Conference Discussion
    May 16 2022

    As 2022 gets underway we check in with a crew of seasoned biotech experts on events in Q1 and the key trends to look out for the rest of the year. Sam Falsetti, Global Chief Biotechnology Officer for MEDiSTRAVA, hosts a wide-ranging discussion with two of his executive colleagues. He is joined by Dean McAllister, EVP, Global Biotech Enterprise Solutions from Ashfield
    Show More Show Less
    41 mins
  • Looking Ahead 2022

    Looking Ahead 2022
    Mar 22 2022

    2021 was a wild ride for biotechnology companies and 2022 is shaping up with some interesting trends that will take biotech into both significant headwinds and opportunities. Sam Falsetti, Global Chief Biotechnology Officer for MEDiSTRAVA, hosts a wide-ranging discussion with two of his executive colleagues. He is joined by Phil Wakefield, the Global Chief Advisory and Evidence Communications Officer for the MEDiSTRAVA group, and Rachel Hatfield, a Managing Partner at MEDiSTRAVA Consulting. They discuss a wide array of topics including lessons learned from 2021, crystal ball predictions for 2022, and key trends that biotech executives should take into account when planning for organizational growth and asset development.

    Show More Show Less
    38 mins
No reviews yet